Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Abemaciclib biedt nieuw perspectief bij de behandeling van gevorderde HR+ HER2- borstkanker
nov 2019 | Borstkanker